22.626 articles found

PHARMACEUTICAL COMPOSITION COMPRISING PRAMIPEXOLE AND AN ANTI-INFLAMMATORY AGENT FOR THE TREATMENT OF PARKINSON'S DISEASE

BUERGER ERICH.

· 2009-07-23

PHARMACEUTICAL COMPOSITION COMPRISING PRAMIPEXOLE AND A CALCIUM CHANNEL BLOCKER FOR THE TREATMENT OF PARKINSON'S DISEASE

BUERGER ERICH, FERGER BORIS, ROHDE FRANK.

· 2009-07-23

Evaluation of a Patient-Specific Index as an outcome measure for physiotherapy in Parkinson's disease.

Nijkrake MJ, Keus SH, Quist-Anholts GW, Overeem S, De Roode MH, Lindeboom R, Mulleners W, Bloem BR, Munneke M.

Eur J Phys Rehabil Med · 2009-07-23

PMID: 20032909

THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN

SUN QUN, WEN KATE XIN, ZHOU XIAOMING.

· 2009-07-20

Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM, 6002-US-051 Study Group.

Parkinsonism Relat Disord · 2009-07-19

DOI: 10.1016/j.parkreldis.2009.06.008PMID: 19616987

Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.

Zádori D, Klivényi P, Vámos E, Fülöp F, Toldi J, Vécsei L.

J Neural Transm (Vienna) · 2009-07-18

DOI: 10.1007/s00702-009-0263-4PMID: 19618107

Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Gal S, Zheng H, Fridkin M, Youdim MB.

Neurotox Res · 2009-07-16

DOI: 10.1007/s12640-009-9070-9PMID: 19609632

Therapeutic extradural cortical stimulation for Parkinson's Disease: report of six cases and review of the literature.

Gutiérrez JC, Seijo FJ, Alvarez Vega MA, Fernández González F, Lozano Aragoneses B, Blázquez M.

Clin Neurol Neurosurg · 2009-07-14

DOI: 10.1016/j.clineuro.2009.06.006PMID: 19604625

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.

Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM, NET-PD Investigators.

Arch Neurol · 2009-07-13

DOI: 10.1001/archneurol.2009.159PMID: 19597081

Compounds, Compositions, and Methods for the Treatment of Synucleinopathies

ESPOSITO LUKE A, CUMMINGS JOEL, HUDSON F MICHAEL, SNOW ALAN D.

· 2009-07-10

NIACIN COMPOSITIONS FOR REDUCTION OF AMYLOID BETA PEPTIDE 42 (ABETA 42) PRODUCTION AND FOR TREATMENT OF ALZHEIMER'S DISEASE (AD)

SAXENA UDAY, AKELLA VENKATESWARLU.

· 2009-07-09

Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)

SAXENA UDAY, AKELLA VENKATESWARULU.

· 2009-07-09